Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 safety study of PGC-005-101 in hospitalized adults with moderate to severe COVID-19
MOH_2022-01-02_010462Phase 2Completed
- Sponsor
- 101 Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PGC-005-101 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by 101 Therapeutics. Primary endpoint: Safety of intravenous PGC-005-101. Started Nov 2021; status: completed.
02
Drugs
PGC-005-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2022-01-02_010462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-02_010462.